Search results

Source:

GOV UK (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 11 December 2014

We have recently advised that talc preparations for pleurodesis are to be considered as medicinal products.

Read Summary

Type:

Safety Alerts (Remove filter)

Source:

GOV UK (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 11 December 2014

Co-proxamol's phased withdrawal period lasts until the end of 2007 to enable patients to move to suitable alternatives.

Read Summary

Type:

Safety Alerts (Remove filter)

Source:

GOV UK (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 11 December 2014

Patients with epilepsy should not take products that contain St John’s wort as any antiepileptic medicine may interact with St John’s wort.

Read Summary

Type:

Safety Alerts (Remove filter)

Source:

GOV UK (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 11 December 2014

MHRA continues to identify cases of herbal medicines, particularly traditional Chinese medicines, which contain illegal and toxic Aristolochia or aristolochic acids.

Read Summary

Type:

Safety Alerts (Remove filter)

Source:

GOV UK (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 11 December 2014

To avoid the risk of air embolism, these products should not be infused under pressure.

Read Summary

Type:

Safety Alerts (Remove filter)

Source:

GOV UK (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 11 December 2014

Products that contain botulinum toxin are associated with the risk of serious adverse reactions due to distant spread of toxin.

Read Summary

Type:

Safety Alerts (Remove filter)

Source:

GOV UK (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 11 December 2014

Paraffin based products such as white soft paraffin can set on fire easily.

Read Summary

Type:

Safety Alerts (Remove filter)

Source:

GOV UK (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 11 December 2014

Detailed recommendations for dose restrictions when used with some other drugs as interactions may increase the risk of adverse effects, or reduce the effectiveness of statin treatment.

Read Summary

Type:

Safety Alerts (Remove filter)

Source:

GOV UK (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 11 December 2014

Advice for healthcare professionals on potentially fatal outcomes of oral anticancer medicines if they are not prescribed, dispensed or administered properly.

Read Summary

Type:

Safety Alerts (Remove filter)

Source:

GOV UK (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 11 December 2014

Healthcare professionals are encouraged to report all suspected adverse reactions (ADRs) on the yellow card porftal to melt formulations of desmopressin.

Read Summary

Type:

Safety Alerts (Remove filter)